Gastroenteropancreatic Neuroendocrine Tumors

U.S. FDA declines to approve two more China-tested drugs

Business, China, Complete Response Letter, FDA, FDA Statements, Gastroenteropancreatic neuroendocrine tumors, Gastroenteropancreatic Neuroendocrine Tumors, Gastrointestinal Tumors, Lung Neuroendocrine Tumors, Nasopharyngeal Carcinoma (NPC), Neuroendocrine Tumors, Oncology, R&D, Shares, Therapeutics, Throat Cancer

The U.S. Food & Drug Administration declined to approve two China-tested cancer treatments on Monday, saying one of the companies – Hutchmed Ltd. – needs to test its drug for the U.S. population in a diverse multi-regional trial.

May 2, 2022/by Christiane Truelove

FDA approves drug for digestive tract cancer

Approvals, Digestive Tract, FDA/Regulatory, Gastroenteropancreatic Neuroendocrine Tumors, Gastrointestinal Tract

The U.S. Food and Drug Administration approved French drugmaker Advanced Accelerator Application SA’s drug to treat patients with a type of digestive tract cancer.

January 26, 2018/by Reuters Health